-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Keji Pharmaceutical-B (02171.HK) announced that the results of the Confirmatory Phase II clinical trial (CT041-ST-01, NCT04581473) of patients with advanced gastro/esophagastric junction adenocarcinoma who were positive for Claudin18.2 and failed at least second-line treatment in China were conducted on May 31, 2025 (UK time) CT041 The full article was published in “The Lancet”, and an oral presentation (Oral Report Session - Gastrointestinal Tumors) was presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on May 31, 2025 (US Central Daylight Time).

Zhitongcaijing·06/02/2025 00:17:00
Listen to the news
Zhitong Finance App News, Keji Pharmaceutical-B (02171.HK) announced that the results of the Confirmatory Phase II clinical trial (CT041-ST-01, NCT04581473) of patients with advanced gastro/esophagastric junction adenocarcinoma who were positive for Claudin18.2 and failed at least second-line treatment in China were conducted on May 31, 2025 (UK time) CT041 The full article was published in “The Lancet”, and an oral presentation (Oral Report Session - Gastrointestinal Tumors) was presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on May 31, 2025 (US Central Daylight Time).